TMSP(SH:600671) Zheng Quan Zhi Xing·2025-08-27 10:06Core Points - The document outlines the information disclosure deferral and exemption management system for Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd, aiming to ensure compliance with legal obligations and protect investors' rights [1][2][3] Group 1: Information Disclosure Management - The company must adhere to various laws and regulations, including the Company Law and Securities Law, while managing information disclosure deferrals and exemptions [1] - Information that involves state secrets or commercial secrets must not be disclosed through any means, including investor interactions and press releases [2][3] - The company can defer or exempt disclosure of information that may lead to unfair competition or harm to its interests or those of others [3][4] Group 2: Conditions for Disclosure Deferral - If the reasons for deferral or exemption are no longer valid, or if the information becomes difficult to keep confidential, timely disclosure is required [5][6] - The definition of commercial secrets includes information that is not publicly known, provides economic benefits, and is protected by confidentiality measures [6][7] Group 3: Internal Review Procedures - A formal internal review process is required for deferring or exempting information disclosure, involving the board secretary and the company chairman [5][6] - The company must maintain records of all deferral and exemption requests for a minimum of 10 years [6] Group 4: Reporting Obligations - After the announcement of annual, semi-annual, or quarterly reports, the company must submit relevant documentation regarding deferred or exempted disclosures to the Zhejiang Securities Regulatory Bureau and the Shanghai Stock Exchange within ten days [6][7] - Any amendments to the system must comply with the latest laws and regulations, and the board is responsible for its formulation and revision [7]